Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery

他喷他多 羟考酮 医学 类阿片 不利影响 麻醉 入射(几何) 内科学 物理 受体 光学
作者
Shania Liu,Asad E. Patanwala,Justine M. Naylor,Jennifer A. Stevens,Bernadette Bugeja,David Begley,Kok Eng Khor,Eric H. Y. Lau,Sam Adie,Jonathan Penm
出处
期刊:The Journal of Pain [Elsevier BV]
卷期号:25 (2): 466-475 被引量:5
标识
DOI:10.1016/j.jpain.2023.09.007
摘要

Oxycodone is a commonly prescribed opioid for postoperative pain. However, there has been a marked increase in the use of tapentadol over the previous decade due to a perceived superior safety profile of tapentadol compared to oxycodone. There is limited real-world evidence on the safety of tapentadol compared to oxycodone after surgery. The primary objective was to examine the impact of tapentadol compared to oxycodone use on the incidence of opioid-related adverse drug events after surgery. Data for adult surgical patients receiving tapentadol or oxycodone during hospitalization between January 1, 2018, and December 31, 2021, were collected from electronic medical records of 3 tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events. Patients receiving tapentadol or oxycodone were matched using nearest-neighbour propensity score matching. In the matched cohorts (n = 1,530 vs n = 2,775; mean [standard deviation] age 62.3 [17.0] years vs 61.9 [standard deviation 17.9] years; 43% vs 45% male for the tapentadol vs oxycodone groups, respectively), patients given tapentadol experienced a similar incidence of adverse events overall (14.4%, 220/1,530 vs 12.6%, 349/2,775; P = .100; 95% CI -.35% to 3.95%). Secondary outcomes included an increased risk of delirium (2.7%, 41/1,530 vs 1.3%, 37/2,775), arrhythmias (3.4%, 52/1,530 vs 2.2%, 62/2,775), and length of hospital stay (5 [range 1-201] vs 4 [range 1-226] days) compared with oxycodone use. Further real-world studies are warranted to determine the impact of tapentadol use on a broad range of patient outcomes. PERSPECTIVE: This study provides an early signal that tapentadol use may be associated with an increased risk of some adverse events and a longer length of stay. Further research is needed to examine the impact of tapentadol use on a broad range of patient outcomes in clinical practice settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎应助hdt采纳,获得10
刚刚
Ava应助合适的彤采纳,获得10
刚刚
悦耳语风完成签到,获得积分10
3秒前
秃头emo兔完成签到 ,获得积分10
4秒前
桐桐应助科研通管家采纳,获得10
4秒前
李健应助科研通管家采纳,获得10
4秒前
帅气书萱应助科研通管家采纳,获得10
4秒前
打打应助科研通管家采纳,获得10
4秒前
今后应助科研通管家采纳,获得10
4秒前
科研通AI2S应助科研通管家采纳,获得10
5秒前
隐形曼青应助科研通管家采纳,获得10
5秒前
Sea_U应助科研通管家采纳,获得10
5秒前
5秒前
魏故完成签到,获得积分10
6秒前
6秒前
yangminghan发布了新的文献求助10
6秒前
gu完成签到,获得积分10
7秒前
里vh完成签到 ,获得积分10
7秒前
ZhouYuqiao完成签到 ,获得积分20
9秒前
杨宇康完成签到,获得积分10
9秒前
kion完成签到,获得积分10
9秒前
晶晶完成签到,获得积分10
11秒前
鲜艳的楼房应助麦丰采纳,获得10
11秒前
13秒前
13秒前
里里完成签到,获得积分10
14秒前
无辜的安容完成签到,获得积分10
14秒前
小五子完成签到,获得积分20
15秒前
勤勤的新星完成签到,获得积分10
15秒前
黄学生完成签到 ,获得积分10
16秒前
SciGPT应助yangminghan采纳,获得20
16秒前
洪豆豆完成签到,获得积分10
19秒前
20秒前
在水一方应助kion采纳,获得10
22秒前
付滋滋完成签到 ,获得积分10
25秒前
搜集达人应助VOIC采纳,获得10
27秒前
29秒前
天天快乐应助zhj采纳,获得10
30秒前
勤恳易真完成签到,获得积分10
31秒前
山海又一程完成签到,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Applied Min-Max Approach to Missile Guidance and Control 5000
Metallurgy at high pressures and high temperatures 2000
Inorganic Chemistry Eighth Edition 1200
The Organic Chemistry of Biological Pathways Second Edition 1000
The Psychological Quest for Meaning 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6326670
求助须知:如何正确求助?哪些是违规求助? 8143408
关于积分的说明 17075145
捐赠科研通 5380287
什么是DOI,文献DOI怎么找? 2854388
邀请新用户注册赠送积分活动 1831959
关于科研通互助平台的介绍 1683204